IMB is a privately held, late stage biotechnology company.  IMB's focus is to commercialize novel products to be used in the treatment of benign and malignant vascularized tumors and hypertrophyic/hyperplastic tissue.  The company's core technology has been developed for the treatment of vascularized cancer tumors, uterine fibroids, and BPH.  


IMB's unique approach in the treatment of hypervascularized tumors and BPH is site specific, and more importantly, biodegradable, giving doctors and patients a safe alternative that allows restoration of the blood supply to the treated organ or tissue.


IMB believes that giving patients and their physicians a safe, easy and effective alternative to surgerical procedures will encourage more patients to seek treatment and find relief from their symptoms. 


For more information on investor participation, please contact us at: